Cargando…
Letter to the editor: Re: Ratti M, Hahne JC, Toppo L, et al. Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data. Ther Adv Med Oncol. 2019
Autor principal: | Ardalan, Bach |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278329/ https://www.ncbi.nlm.nih.gov/pubmed/32550866 http://dx.doi.org/10.1177/1758835920928636 |
Ejemplares similares
-
Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data
por: Ratti, Margherita, et al.
Publicado: (2019) -
Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
por: Nakai, Hidekatsu, et al.
Publicado: (2023) -
Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’
por: Hettle, Robert, et al.
Publicado: (2023) -
Letter to the Editor Re: Ahn DH, Krishna K, Blazer M, et al. “A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.” Ther Adv Med Oncol https://doi.org/10.1177/1758834016676011
por: Von Hoff, Daniel D, et al.
Publicado: (2017) -
Hahn’s False Move
Publicado: (2009)